Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOLACE: DEB-TACE vs Sorafenib in HCC
NCT02460991Phase 3Terminated
- Sponsor
- Boston Scientific Corporation
- Start
- Nov 2015
- Primary completion
- Jun 2017
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial (2 arms), sponsored by Boston Scientific Corporation. Primary endpoint: Overall Survival at 1 year. Started Nov 2015; status: terminated.
Beyond the preview
Go deeper on NCT02460991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02460991.